Endometrial cancer, the most prevalent gynecological malignancy in developed countries, is experiencing a sustained rise in both its incidence and mortality rates, primarily attributed to extended life expectancy and lifestyle factors. Currently, the absence of precise diagnostic tools hampers the effective management of the expanding population of women at risk of developing this disease. Furthermore, patients diagnosed with endometrial cancer require precise risk stratification to align with optimal treatment planning. Metabolomics technology offers a unique insight into the molecular landscape of endometrial cancer, providing a promising approach to address these unmet needs. This comprehensive literature review initiates with an overview of metabolomic technologies and their intrinsic workflow components, aiming to establish a fundamental understanding for the readers. Subsequently, a detailed exploration of the existing body of research is undertaken with the objective of identifying metabolite biomarkers capable of enhancing current strategies for endometrial cancer diagnosis, prognosis, and recurrence monitoring. Metabolomics holds vast potential to revolutionize the management of endometrial cancer by providing accuracy and valuable insights into crucial aspects.
子宫内膜癌作为发达国家中最常见的妇科恶性肿瘤，其发病率和死亡率持续上升，主要归因于预期寿命延长及生活方式因素。目前，由于缺乏精准的诊断工具，对日益增长的子宫内膜癌高危女性群体的有效管理受到制约。此外，确诊患者需要精确的风险分层以匹配最佳治疗方案。代谢组学技术为子宫内膜癌的分子特征提供了独特视角，为解决这些未满足的临床需求带来了新希望。本文献综述首先概述代谢组学技术及其基本工作流程，旨在为读者建立基础认知框架。随后系统梳理现有研究，重点探索能够提升子宫内膜癌诊断、预后判断及复发监测效能的代谢物生物标志物。代谢组学通过提供精准检测手段及关键临床环节的深入洞见，在革新子宫内膜癌诊疗管理体系方面展现出巨大潜力。
Metabolomic-Based Approaches for Endometrial Cancer Diagnosis and Prognosis: A Review
肿瘤(癌症)患者之家